No statistical difference observed between 2 studied dosing regimens SAN DIEGO, Oct. 26 (HSMN NewsFeed) — According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - …
Biopharmaceuticals, Gastroenterology
UCB, WELCOME trial, CIMZIA, certolizumab pegol, Crohn’s disease

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure”
Leave a Comment